Compares two keyhole robotic surgery methods for localized prostate cancer
Compares single-port and multi-port robotic prostate removal in men with localized prostate cancer.
Plain-language title generated from the registry record
Registry title: Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP)
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06238713, who can take part
Where in China
- Changzheng HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Changzheng Hospital
- Trial code
- NCT06238713
- Record updated
- 23 July 2026
- Original description
This study is a two-arm, multicenter, randomized controlled clinical trial on whether single-port extraperitoneal VIP RARP is non-inferior to multi-port transperitoneal RARP in terms of functional recovery rate and other key metrics.Read full original descriptionShow less
Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP)
This study is a two-arm, multicenter, randomized controlled clinical trial on whether single-port extraperitoneal VIP RARP is non-inferior to multi-port transperitoneal RARP in terms of functional recovery rate and other key metrics.
Inclusion: Men aged 18 years ≤ age ≤ 75 years; Prostate biopsy within 6 months with diagnosis of organ-localized prostate cancer with preoperative staging of T1c to T2b,N0M0; Gleason Score<8; PSA<20ng/ml; Pathologic diagnosis of prostate follicular adenocarcinoma or prostate ductal adenocarcinoma; The patient has healthy sexual function before surgery and intention for sexual activities after surgery; Physiological condition acceptable for laparoscopic surgery; Willing to cooperate and complete the study follow-up and related examinations; The subject or his agent voluntarily participates in this trial and signs the written informed consent; The questionnaire can be completed in Chinese; The patient has been informed of the trial.
Exclusion: History of previous abdominal surgery and radiotherapy which may affect abdominal incision and Port placement; Patients who have undergone previous electro-prostatectomy/enucleation of the prostate; had received any type of preoperative antitumor therapy; Participation in other clinical studies or previous treatment with any gene therapy product within the last 3 months; High-risk and non-organ localized prostate cancer (clinical stage ≥ T2c, GS ≥ 8, PSA > 20ng/ml); Special type of prostate cancer， such as neuroendocrine etc; Recent surgery of rectum, perianal abscess or around fistula and perineal area; Suffering from poor general condition with the presence of one of the following conditions: including severe mental disorders, cardiovascular disease, active infections, bone marrow transplantation within 3 months, or significant abnormalities in organ function; Other conditions that the researchers believe may affect the experimental results or are unethical; Non-recurrent patients with less than 12 months of follow-up; ECOG>1; Combination of other systemic tumors.